Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response - Wikidata - awgldk - TriplyDB

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

http://www.wikidata.org/entity/Q36402967

about

Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future Directions Targeting the indoleamine 2,3-dioxygenase pathway in cancer Relevance of tumor-infiltrating lymphocytes in breast cancer Vaccines for pancreatic cancer Allogeneic tumor cell vaccines: the promise and limitations in clinical trials Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy The interplay of immunotherapy and chemotherapy: harnessing potential synergies Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells Immunosuppressive strategies that are mediated by tumor cells Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine In vivo imaging of T cell delivery to tumors after adoptive transfer therapy.IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice Stromal reengineering to treat pancreas cancer Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.Features of responding T cells in cancer and chronic infection.Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma Chemoimmunotherapy.Up-regulation of Th17 cells may underlie inhibition of Treg development caused by immunization with activated syngeneic T cells.Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.Neoadjuvant anti-tumor vaccination prior to surgery enhances survival.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation.A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.

P2860

Q24610550-CC9AA5B5-5633-4115-980F-150E89851B5C Q26771113-CE308363-8EC8-475A-A8AE-2B5D7484937B Q26775471-0C087F95-682E-4CDE-BFDD-C9B912FB56A5 Q26795598-AF776391-D77D-4C82-826F-A4D2B29A1D65 Q26825850-60CFCD22-B0D2-43A2-8B4A-C98AF696EB2B Q26852333-7AD635E1-80CF-43E8-A03D-D631E63D1646 Q27009908-345BEE9F-11D4-4054-A132-D88678C036CA Q27027093-AB7FB100-B3C5-4E6E-B7D4-E33D28018251 Q28081893-7F3AC4F6-C3E4-4F7A-BF08-70FACE4479D4 Q28732041-83563FFF-8D0D-4310-88CB-0B406C8D26CC Q29636247-18BCDB3C-87C8-4DE2-B450-D7841A6BD140 Q30425914-F954A133-C65C-49DF-BB9A-58A9945F41DC Q30479855-AE3B36ED-2BAB-4B8D-8381-76155D227536 Q30481064-57B6E9DF-C28F-47E1-B174-964EC97714A9 Q33299427-FA1B8C4A-6B60-40E9-9DBD-5F1153977DDF Q33502208-7EA65CC2-5436-4EDF-BA61-B5D3D11AF1DD Q33579629-E60E5DCB-9544-44F7-AA23-5C35AA8A5B24 Q33614657-BAA9F314-FE6B-453B-8C91-FA5AB7FBFF99 Q33653210-1C26EBE7-FDEC-4F38-9C03-DBAB205EBA08 Q33738279-62DEE8A5-3192-44A3-9743-0DE4C65A2941 Q33773435-59F17FE0-109D-4D9B-964D-7AE1AD9E9450 Q33823499-A3C0C8A5-D118-479D-A48E-7A5FF816F789 Q33827708-4DBF62F8-B5A3-45EB-8A98-B83DAA6747B4 Q33848077-3034EBC2-5FF9-4DEB-B210-28D7CC08F7F4 Q33871059-6B2A46B3-C48E-448E-85D7-4F2B12B5A307 Q33887648-E84A6B1E-67CE-4597-AEA9-5DFD11C14DF2 Q33941340-35CB0CBA-F79F-4B4B-B743-D9E0E14F484B Q34013869-E750F41D-CCAC-4DCD-9AAC-94007F52095B Q34014497-F737DDFF-842C-4E53-B2E7-F1F3CA5FEF11 Q34058792-34D76D32-F2D8-475F-A2DA-854BE6492C7E Q34075574-883B5BF4-EDFB-4778-B318-8825C278CC45 Q34082964-F28CB954-BB07-4F87-B470-A7BFFBA7BD70 Q34145877-2991729F-AAD5-4508-BB40-08ED372A0640 Q34187201-0A2E67A9-AFD7-4E2A-ABB5-9802B240C8AC Q34315863-96E399A6-D96E-4310-BD68-3E12521E3ADC Q34330865-91C3DB1A-DF63-44AB-A6EB-F655D0D97185 Q34412289-E8B2376F-104A-4FB3-879E-50C8E3E0361D Q34477650-9154B5D1-CB5F-44FD-96AD-1C761D56F41C Q34556927-033364B0-5489-4C06-B30E-CD6DAC02E918 Q34557233-1C046DB8-DF69-4805-ADF4-72DCE83ED310

P2860

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

http://www.wikidata.org/entity/Q36402967

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Recruitment of latent pools of ...... the antitumor immune response

@ast

Recruitment of latent pools of ...... the antitumor immune response

@en

type

label

Recruitment of latent pools of ...... the antitumor immune response

@ast

Recruitment of latent pools of ...... the antitumor immune response

@en

prefLabel

Recruitment of latent pools of ...... the antitumor immune response

@ast

Recruitment of latent pools of ...... the antitumor immune response

@en

P1433

Q36402967-F6072CC7-96D2-449C-910F-306A967FEB6D

P1476

Q36402967-7E2F3A8C-6B55-4DDB-92D5-E0C52985236D

P2093

Q36402967-499F8031-D30A-4EBD-A830-AAF298DA20AD

Q36402967-4F4492D8-4400-42C3-839C-83DD7AF59BD0

Q36402967-81E5B77C-8021-4FB8-ACAB-650B967E5A06

Q36402967-88BAD420-E949-472E-A624-EFE5C7F2E030

Q36402967-B4B2E53C-DA59-4189-94B8-5C27778904FB

Q36402967-D312BE98-CFD2-42B9-8E6C-396DE29CD219

Q36402967-D77001E9-D43F-4AED-9EBB-CA0C3FE03D96

Q36402967-E1D5F0D6-E719-431C-B67D-479A61166EFF

Q36402967-E1E981CC-700C-49AC-A563-B831A3FF9F5E

P2860

Q36402967-03E89830-F826-49B5-BD2F-2D883AF7D225

Q36402967-0735B421-914C-4B8E-B4B1-05C04573C992

Q36402967-0B8D3B36-080A-4C18-B20A-A00D147C42AF

Q36402967-0F2B9504-B7C8-4886-BC67-72B3444F50EE

Q36402967-1105AC79-F7E1-41FF-8B5F-3AE10FB3801A

Q36402967-17EDCA69-66FA-4383-B143-41D88077A5B9

Q36402967-18B77D59-F0BD-4122-8125-0619B8D8D42B

Q36402967-1AE564C5-15AF-4631-B92E-0CEC577169E7

Q36402967-30EF9210-B275-4FE2-953B-6F32E173C168

Q36402967-3342B013-D9C2-4035-976B-47DCE00CA671

P304

Q36402967-B2BA103A-6A4F-4008-BFA2-CF589E42CEA8

P31

Q36402967-25B0D557-D2F7-40BF-A008-01169F1C641E

P356

Q36402967-68043B75-AEF8-4DB8-B1D0-1FE4D8C1B981

P407

Q36402967-8B6CD0DB-02C7-4CD8-91E3-C5A175868B14

P433

Q36402967-20E27518-64DF-4A3D-9523-EF7946ECF62C

P478

Q36402967-A01A37F2-ABC5-423F-B6C7-DBE8BD35BC6D

P50

Q36402967-C36E393C-2614-446C-99B1-0DFBFC0E8724

P577

Q36402967-9099F7B2-1AC4-45FE-A34A-611660A90B13

P5875

Q36402967-5173E19F-099C-47FA-9195-CCB643A56A8F

P698

Q36402967-01D5467A-3167-4B94-936A-35295C361D3B

P932

Q36402967-DA6D583D-F3ED-4C46-865C-134177EF74E3

P356

P1433

Journal of Experimental Medicine

P1476

Recruitment of latent pools of ...... the antitumor immune response

@en

P2093

Anne M Ercolini

http://www.w3.org/2001/XMLSchema#string

Brian H Ladle

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Manning

http://www.w3.org/2001/XMLSchema#string

Jean-Pascal H Machiels

http://www.w3.org/2001/XMLSchema#string

Joan G Bieler

http://www.w3.org/2001/XMLSchema#string

Leisha A Emens

http://www.w3.org/2001/XMLSchema#string

Lukas W Pfannenstiel

http://www.w3.org/2001/XMLSchema#string

R Todd Reilly

http://www.w3.org/2001/XMLSchema#string

Todd D Armstrong

http://www.w3.org/2001/XMLSchema#string

P2860

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Control of regulatory T cell development by the transcription factor Foxp3

Phenotypic analysis of antigen-specific T lymphocytes

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

Studying cancer in the mouse.

Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

The enemy within: keeping self-reactive T cells at bay in the periphery.

P304

1591-1602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20042167

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

201

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth Jaffee

P577

2005-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7858282

http://www.w3.org/2001/XMLSchema#string

P698

15883172

http://www.w3.org/2001/XMLSchema#string

P932

2212915

http://www.w3.org/2001/XMLSchema#string